{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:36:39Z","timestamp":1790778999264,"version":"4.1.0"},"reference-count":143,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.pharmthera.2011.05.004","type":"journal-article","created":{"date-parts":[[2011,5,22]],"date-time":"2011-05-22T13:38:48Z","timestamp":1306071528000},"page":"1-14","source":"Crossref","is-referenced-by-count":43,"title":["Congenital adrenal hyperplasia \u2014 Pharmacologic interventions from the prenatal phase to adulthood"],"prefix":"10.1016","volume":"132","author":[{"given":"H.L.","family":"Claahsen-van der Grinten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.M.M.L.","family":"Stikkelbroeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.J.","family":"Otten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.M.M.","family":"Hermus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2011.05.004_bb0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2265.2007.02763.x","article-title":"Modulation of glucocorticoid metabolism by the growth hormone\u2013IGF-1 axis","volume":"66","author":"Agha","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"10.1016\/j.pharmthera.2011.05.004_bb0010","doi-asserted-by":"crossref","first-page":"7484","DOI":"10.1073\/pnas.062170099","article-title":"Adenoviral vectors can impair adrenocortical steroidogenesis: clinical implications for natural infections and gene therapy","volume":"99","author":"Alesci","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0015","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1210\/jc.2006-0674","article-title":"Review: Hypothalamic pituitary adrenal function during critical illness: limitations of current assessment methods","volume":"91","author":"Arafah","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0020","article-title":"The United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE)","volume":"18","author":"Arlt","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF03346799","article-title":"Reversible male infertility in late onset congenital adrenal hyperplasia","volume":"14","author":"Augarten","year":"1991","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0030","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/326275","article-title":"Bone health should be an important concern in the care of patients affected by 21 hydroxylase deficiency","author":"Bachelot","year":"2010","journal-title":"Int J Pediatr Endocrinol"},{"issue":"12","key":"10.1016\/j.pharmthera.2011.05.004_bb0040","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1210\/jc.2003-030123","article-title":"CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency","volume":"88","author":"Balsamo","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"4\u20135","key":"10.1016\/j.pharmthera.2011.05.004_bb0045","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000315959","article-title":"Impact of molecular genetics on congenital adrenal hyperplasia management","volume":"4","author":"Balsamo","year":"2010","journal-title":"Sex Dev"},{"issue":"5","key":"10.1016\/j.pharmthera.2011.05.004_bb0050","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1210\/jc.2008-1582","article-title":"Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members","volume":"94","author":"Bidet","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.pharmthera.2011.05.004_bb0055","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1210\/jc.2009-1383","article-title":"Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"95","author":"Bidet","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.pharmthera.2011.05.004_bb0060","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0022-3476(99)70413-0","article-title":"Home monitoring of 17 hydroxyprogesterone levels in congenital adrenal hyperplasia with filter paper blood samples","volume":"134","author":"Bode","year":"1999","journal-title":"J Pediatr"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0065","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1210\/jc.2006-2109","article-title":"Reduced final height outcome in congenital adrenal hyperplasia and prednisone treatment: deceleration of growth velocity during puberty","volume":"92","author":"Bonfig","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0070","first-page":"934","article-title":"Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence based recommendation","volume":"9","author":"Bonfig","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmthera.2011.05.004_bb0075","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1210\/en.139.4.1546","article-title":"Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary\u2013adrenal function, body weight, and metabolic regulation","volume":"139","author":"Bornstein","year":"1998","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.pharmthera.2011.05.004_bb0080","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00431-004-1572-0","article-title":"Plasma aldosterone levels in the 1st week of life in infants of less than 30weeks gestation","volume":"164","author":"Bourchier","year":"2005","journal-title":"Eur J Pediatr"},{"issue":"9","key":"10.1016\/j.pharmthera.2011.05.004_bb0085","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1210\/jc.2009-0630","article-title":"Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion","volume":"94","author":"Bryan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.pharmthera.2011.05.004_bb0090","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1210\/jc.2004-1056","article-title":"On the interactions of the hypothalamic\u2013pituitary\u2013adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders","volume":"90","author":"Buckley","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.pharmthera.2011.05.004_bb0095","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/09513590902730754","article-title":"Hepatotoxicity during low-dose flutamide treatment for hirsutism","volume":"25","author":"Castelo-Branco","year":"2009","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0100","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpurol.2010.05.004","article-title":"Bilateral simultaneous laparoscopic adrenalectomy for congenital adrenal hyperplasia: initial experience","volume":"7","author":"Castillo","year":"2011","journal-title":"J Pediatr Urol"},{"issue":"6","key":"10.1016\/j.pharmthera.2011.05.004_bb0105","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1530\/EJE-07-0887","article-title":"Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency","volume":"158","author":"Chakhtoura","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1677\/joe.0.1690065","article-title":"Bioavailablility of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"169","author":"Charmandari","year":"2001","journal-title":"J Endocrinol"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0115","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1210\/jc.86.10.4679","article-title":"Serum Cortisol and 17 hydroxyprogesterone interrelation in classic 21-hydroxylase deficiency: is current replacement therapy satisfactory?","volume":"86","author":"Charmandari","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/adc.85.1.26","article-title":"Congenital adrenal hyperplasia: management during critical illness","volume":"85","author":"Charmandari","year":"2001","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0125","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1210\/jc.86.6.2701","article-title":"Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty","volume":"86","author":"Charmandari","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0130","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/adc.86.4.266","article-title":"Why is management of patients with congenital adrenal hyperplasia more difficult at puberty?","volume":"86","author":"Charmandari","year":"2002","journal-title":"Arch Dis Child"},{"issue":"4","key":"10.1016\/j.pharmthera.2011.05.004_bb0135","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1515\/JPEM.2002.15.4.435","article-title":"Treatment with flutamide decreases cortisol clearance: implications for therapy in congenital adrenal hyperplasia","volume":"15","author":"Charmandari","year":"2002","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0140","doi-asserted-by":"crossref","first-page":"U77","DOI":"10.1530\/eje.0.151U077","article-title":"Classic congenital adrenal hyperplasia and puberty","volume":"151","author":"Charmandari","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.pharmthera.2011.05.004_bb0145","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1515\/JPEM.2005.18.1.97","article-title":"Adrenocorticotropin hypersecretion and pituitary microadenoma following bilateral adrenalectomy in a patient with classic 21-hydroxylase deficiency","volume":"18","author":"Charmandari","year":"2005","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.pharmthera.2011.05.004_bb0150","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1515\/JPEM.2006.19.5.677","article-title":"Fertility in patients with congenital adrenal hyperplasia","volume":"19","author":"Claahsen-van der Grinten","year":"2006","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmthera.2011.05.004_bb0155","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1210\/jc.2005-1701","article-title":"Absence of increased height velocity in the first year of life in untreated children with simple virilizing congenital adrenal hyperplasia","volume":"91","author":"Claahsen-van der Grinten","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.pharmthera.2011.05.004_bb0160","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.fertnstert.2006.11.148","article-title":"Repeated successful induction of fertility after replacing hydrocortisone with dexamethasone in a patient with congenital adrenal hyperplasia and testicular adrenal rest tumors","volume":"88","author":"Claahsen-van der Grinten","year":"2007","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.pharmthera.2011.05.004_bb0165","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1210\/jc.2006-1311","article-title":"Testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia: evaluation of pituitary\u2013gonadal function before and after successful testis-sparing surgery in eight patients","volume":"92","author":"Claahsen-van der Grinten","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.pharmthera.2011.05.004_bb0170","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1530\/EJE-07-0201","article-title":"Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"157","author":"Claahsen-van der Grinten","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.pharmthera.2011.05.004_bb0175","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.fertnstert.2007.03.051","article-title":"Testicular adrenal rest tumors in patients with congenital adrenal hyperplasia can cause severe testicular damage","volume":"89","author":"Claahsen-van der Grinten","year":"2008","journal-title":"Fertil Steril"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0180","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/624823","article-title":"Testicular adrenal rest tumours in congenital adrenal hyperplasia","author":"Claahsen-van der Grinten","year":"2009","journal-title":"Int J Pediatr Endocrinol"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0185","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000065490","article-title":"Consensus statement on 21-hydroxylase deficiency from the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society","volume":"58","author":"Clayton","year":"2002","journal-title":"Horm Res"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0190","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/347636","article-title":"Nocturnal dexamethasone versus hydrocortisone for the treatment of children with congenital adrenal hyperplasia","author":"Dauber","year":"2010","journal-title":"Int J Pediatr Endocrinol"},{"issue":"5","key":"10.1016\/j.pharmthera.2011.05.004_bb0195","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0022-3476(84)80310-8","article-title":"Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency","volume":"105","author":"David","year":"1984","journal-title":"J Pediatr"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0200","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1515\/JPEM.2004.17.8.1089","article-title":"24-hour ambulatory blood pressure profile in patients with congenital adrenal hyperplasia\u2014a preliminary report","volume":"17","author":"De Silva","year":"2004","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.pharmthera.2011.05.004_bb0205","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1210\/en.140.1.79","article-title":"The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress","volume":"140","author":"Deak","year":"1999","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.pharmthera.2011.05.004_bb0210","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.beem.2008.09.010","article-title":"Novel strategies for hydrocortisone replacement","volume":"23","author":"Debono","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0215","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/j.1552-4604.1991.tb01906.x","article-title":"Pharmacokinetics and oral bioavailability of hydrocortisone","volume":"31","author":"Derendorf","year":"1991","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 5","key":"10.1016\/j.pharmthera.2011.05.004_bb0220","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000110587","article-title":"Growth in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"68","author":"D\u00f6rr","year":"2007","journal-title":"Horm Res"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0225","doi-asserted-by":"crossref","unstructured":"Dunkel, L. (2006) Use of aromatase inhibitors to increase final height. Mol Cell Endocrinol. 25; 254\u2013255:207\u201316.","DOI":"10.1016\/j.mce.2006.04.031"},{"issue":"3","key":"10.1016\/j.pharmthera.2011.05.004_bb0230","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00024677-200403030-00002","article-title":"Aromatase inhibitors in precocious puberty: rationale and experience to date","volume":"3","author":"Eugster","year":"2004","journal-title":"Treat Endocrinol"},{"issue":"1","key":"10.1016\/j.pharmthera.2011.05.004_bb0235","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1067\/mpd.2001.110527","article-title":"Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis","volume":"138","author":"Eugster","year":"2001","journal-title":"J Pediatr"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0240","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1365-2265.2010.03826.x","article-title":"Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical congenital adrenal hyperplasia due to 21hydroxylase (CYP21A2) deficiency: a systematic review and meta-analyses","volume":"73","author":"Fern\u00e1ndez-Balsells","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0245","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2010-0319","article-title":"Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"96","author":"Finkielstain","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0250","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/712549","article-title":"Duration of suppression of adrenal steroids after glucocorticoid administration","author":"Fuqua","year":"2010","journal-title":"Int J Pediatr Endocrinol"},{"issue":"12","key":"10.1016\/j.pharmthera.2011.05.004_bb0255","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1210\/jc.2008-0519","article-title":"Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoide therapy","volume":"93","author":"German","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.pharmthera.2011.05.004_bb0260","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.1542\/peds.109.2.e28","article-title":"Bilateral laparoscopic adrenalectomy as a treatment for classic congenital adrenal hyperplasia attributable to 21-hydroxylase deficiency","volume":"109","author":"Gmyrek","year":"2002","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.pharmthera.2011.05.004_bb0265","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1210\/en.135.4.1470","article-title":"Survival of steroid 21-hydroxylase-deficient mice without endogenous corticosteroids after neonatal treatment and genetic rescue by transgenesis as a model system for treatment of congenital adrenal hyperplasia in humans","volume":"135","author":"Gotoh","year":"1994","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.pharmthera.2011.05.004_bb0270","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1373\/49.10.1688","article-title":"Circadian rhythm of salivary cortisol, 17alpha-hydroxyprogesterone, and progesterone in healthy children","volume":"49","author":"Gr\u00f6schl","year":"2003","journal-title":"Clin Chem"},{"issue":"7","key":"10.1016\/j.pharmthera.2011.05.004_bb0275","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/humrep\/den118","article-title":"Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"23","author":"Hagenfeldt","year":"2008","journal-title":"Hum Reprod"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0280","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.beem.2008.09.009","article-title":"Therapeutic managemant of adrenal insufficiency","volume":"23","author":"Hahner","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmthera.2011.05.004_bb0285","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000049990","article-title":"Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Result of a multicenter study","volume":"55","author":"Hargitai","year":"2001","journal-title":"Horm Res"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0740","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2125.1984.tb04999.x","article-title":"Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability","volume":"17","author":"Heazelwood","year":"1984","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.pharmthera.2011.05.004_bb0290","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1210\/jc.2005-0324","article-title":"Circulating antiandrogenic activity in children with congenital adrenal hyperplasia during peroral flutamide treatment","volume":"90","author":"Hero","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0295","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.beem.2008.10.010","article-title":"Management of the child with congenital adrenal hyperplasia","volume":"23","author":"Hindmarsh","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0300","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1515\/JPEM.2006.19.5.705","article-title":"Blood pressure in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"19","author":"Hoepffner","year":"2006","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"Suppl 5","key":"10.1016\/j.pharmthera.2011.05.004_bb0305","first-page":"1329","article-title":"Congenital adrenal hyperplasia: phenotype and genotype","volume":"15","author":"Hughes","year":"2002","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0315","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1210\/jc.76.6.1505","article-title":"Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolutkon analysis","volume":"76","author":"Kerringan","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0320","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1210\/jc.85.3.1059","article-title":"Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany","volume":"85","author":"Krone","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"3\u20135","key":"10.1016\/j.pharmthera.2011.05.004_bb0325","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jsbmb.2010.04.010","article-title":"Gas chromatography\/mass spectrometry (GC\/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC\/MS\/MS)","volume":"121","author":"Krone","year":"2010","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"10","key":"10.1016\/j.pharmthera.2011.05.004_bb0330","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1210\/jc.81.10.3535","article-title":"A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia","volume":"81","author":"Laue","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0335","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0022-3476(05)80128-3","article-title":"Cortisol production rate in childhood and adolescence","volume":"117","author":"Linder","year":"1990","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.pharmthera.2011.05.004_bb0340","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1210\/jc.2004-2128","article-title":"Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia","volume":"90","author":"Lin-Su","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0345","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/670960","article-title":"Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises","author":"Loechner","year":"2010","journal-title":"Int J Pediatr Endocrinol"},{"issue":"1","key":"10.1016\/j.pharmthera.2011.05.004_bb0350","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1530\/EJE-07-0052","article-title":"Continuous subcutaneous hydrocortisone infusion in Addison's disease","volume":"157","author":"L\u00f8v\u00e5s","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.pharmthera.2011.05.004_bb0355","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2265.2004.02106.x","article-title":"Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency","volume":"61","author":"Mah","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1016\/j.pharmthera.2011.05.004_bb0360","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1203\/PDR.0b013e3181b1bbec","article-title":"Physiological partial aldosterone resistance in human newborns","volume":"66","author":"Martinerie","year":"2009","journal-title":"Pediatr Res"},{"issue":"3","key":"10.1016\/j.pharmthera.2011.05.004_bb0365","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1210\/jc.2007-2417","article-title":"Approach to the adult with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"93","author":"Merke","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"9477","key":"10.1016\/j.pharmthera.2011.05.004_bb0370","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(05)66736-0","article-title":"Congenital adrenal hyperplasia","volume":"365","author":"Merke","year":"2005","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.pharmthera.2011.05.004_bb0375","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.277.13.1073","article-title":"New approaches to the treatment of congenital adrenal hyperplasia","volume":"277","author":"Merke","year":"1997","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.pharmthera.2011.05.004_bb0380","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1210\/jc.85.3.1114","article-title":"Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia","volume":"85","author":"Merke","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"10.1016\/j.pharmthera.2011.05.004_bb0385","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJM200011093431903","article-title":"Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency","volume":"343","author":"Merke","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmthera.2011.05.004_bb0390","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1210\/jc.86.1.441","article-title":"Hydrocortisone suspension and hydrocortisone tablets are not bioequivalent in the treatment of children with congenital adrenal hyperplasia","volume":"86","author":"Merke","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmthera.2011.05.004_bb0395","doi-asserted-by":"crossref","first-page":"320","DOI":"10.7326\/0003-4819-136-4-200202190-00012","article-title":"NIH conference. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"136","author":"Merke","year":"2002","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.pharmthera.2011.05.004_bb0400","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2265.2006.02544.x","article-title":"Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia","volume":"65","author":"Merza","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0405","series-title":"Clinical paediatric endocrinology","article-title":"The adrenal cortex and its disorders","author":"Miller","year":"2001"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0410","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2265.2009.03690.x","article-title":"Unfavourable trends in cardiovascular and metabolic risk in paediatric and adult patients with congenital adrenal hyperplasia","volume":"73","author":"Mooij","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0415","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1210\/jc.84.11.4172","article-title":"Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies","volume":"84","author":"Moore","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.pharmthera.2011.05.004_bb0420","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1210\/jc.2006-0062","article-title":"Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia","volume":"91","author":"Moran","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.pharmthera.2011.05.004_bb0425","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2605.2009.00958.x","article-title":"Improvement of semen quality in an infertile man with 21-hydroxylase deficiency, suppressed serum gonadotropins and testicular adrenal rest tumours","volume":"33","author":"Mouritsen","year":"2010","journal-title":"Int J Androl"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0430","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1067\/mpd.2002.126601","article-title":"Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia","volume":"141","author":"Muirhead","year":"2002","journal-title":"J Pediatr"},{"issue":"9","key":"10.1016\/j.pharmthera.2011.05.004_bb0435","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1210\/jc.2009-2616","article-title":"Clinical review: adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis","volume":"95","author":"Muthusamy","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0440","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s12020-006-0005-4","article-title":"Observation of hypertension in children with 21-hydroxylase deficiency. A preliminary report","volume":"30","author":"Nebesio","year":"2006","journal-title":"Endocrine"},{"issue":"11","key":"10.1016\/j.pharmthera.2011.05.004_bb0445","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1210\/jc.2006-1645","article-title":"Nonclassical 21-hydroxylase deficiency","volume":"91","author":"New","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0450","first-page":"91","article-title":"Growth and final height in classical and nonclassical 21-hydroxylase deficiency","volume":"12","author":"New","year":"1989","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"10.1016\/j.pharmthera.2011.05.004_bb0455","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1365-2265.2007.03011.x","article-title":"Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers","volume":"68","author":"Newell-Price","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0460","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0140-6736(90)90289-H","article-title":"Self-management of adrenal insufficiency by rectal hydrocortisone","volume":"335","author":"Newrick","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0465","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1515\/JPEM.2003.16.8.1101","article-title":"Rectal hydrocortisone during vomiting in children with adrenal insufficiency","volume":"16","author":"Ni Chroinin","year":"2003","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0470","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00006454-198901000-00005","article-title":"Serum cortisol responses in febrile children","volume":"8","author":"Nickels","year":"1989","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.pharmthera.2011.05.004_bb0475","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1210\/jc.2006-0964","article-title":"Aldosterone-to-renin ratio as a marker for disease severity in 21-hydroxylase deficiency congenital adrenal hyperplasia","volume":"92","author":"Nimkarn","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0480","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1530\/EJE-10-0863","article-title":"\u201cEmpty sella syndrome\u201d: a case of a patient with sodium-succinate hydrocortisone allergy","volume":"164","author":"Nucera","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0485","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/0039-128X(96)00007-4","article-title":"Effects of estrogens and progesterons on the renin\u2013aldosterone system and blood pressure","volume":"61","author":"Oelkers","year":"1996","journal-title":"Steroids"},{"issue":"3","key":"10.1016\/j.pharmthera.2011.05.004_bb0490","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/eje.1.02096","article-title":"Outcome of bilateral adrenalectomy in congenital adrenal hyperplasia: one unit's experience","volume":"154","author":"Ogilvie","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0495","series-title":"Male hypogonadism: basic, clinical and therapeutic principles","article-title":"Hypogonadism in males with congenital adrenal hyperplasia","author":"Otten","year":"2004"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0500","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/656925","article-title":"Mineralocorticoid deficiency and treatment in congenital adrenal hyperplasia","author":"Padidela","year":"2010","journal-title":"Int J Pediatr Endocrinol"},{"issue":"3","key":"10.1016\/j.pharmthera.2011.05.004_bb0505","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1067\/S0022-3476(03)00294-4","article-title":"Prednisolone in the treatment of adrenal insufficiency: a re-evaluation of relative potency","volume":"143","author":"Punthakee","year":"2003","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.pharmthera.2011.05.004_bb0510","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1210\/jc.86.4.1511","article-title":"Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia","volume":"86","author":"Quintos","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.pharmthera.2011.05.004_bb0515","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.steroids.2006.01.015","article-title":"Automated, fast and sensitive quantification of 17 alpha-hydroxy-progesterone, androstenedione and testosterone by tandem mass spectrometry with on-line extraction","volume":"71","author":"Rauh","year":"2006","journal-title":"Steroids"},{"issue":"5","key":"10.1016\/j.pharmthera.2011.05.004_bb0520","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1210\/jc.2008-1414","article-title":"High prevalence of reduced fecundity in males with congenital adrenal hyperplasia","volume":"94","author":"Reisch","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0525","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000065492","article-title":"Management of congenital adrenal hyperplasia: results of the ESPE questionnaire","volume":"58","author":"Riepe","year":"2002","journal-title":"Horm Res"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0535","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/569680","article-title":"Dexamethasone therapy of congenital adrenal hyperplasia and the myth of the \u201cgrowth toxic\u201d glucocorticoid","author":"Rivkees","year":"2010","journal-title":"Int J Pediatr Endocrinol"},{"issue":"4","key":"10.1016\/j.pharmthera.2011.05.004_bb0540","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1542\/peds.106.4.767","article-title":"Dexamethasone treatment of virilizing congenital adrenal hyperplasia: the ability to achieve normal growth","volume":"106","author":"Rivkees","year":"2000","journal-title":"Pediatrics"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0545","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/274682","article-title":"Low-dose dexamethasone therapy from infancy of virilizing congenital adrenal hyperplasia","author":"Rivkees","year":"2009","journal-title":"Int J Pediatr Endocrinol"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0550","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1046\/j.1365-2265.2003.01757.x","article-title":"Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report","volume":"58","author":"Roche","year":"2003","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0555","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1210\/jc.87.6.2993","article-title":"Serum cortisol and 17-hydroxyprogesterone concentrations in children with classic congenital adrenal hyperplasia","volume":"87","author":"Rosenfield","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0560","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1210\/jcem-45-3-500","article-title":"The interrelationship of sodium balance, plasma renin activity and ACTH in congenital adrenal hyperplasia","volume":"45","author":"R\u00f6sler","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.pharmthera.2011.05.004_bb0565","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1210\/jc.2006-1711","article-title":"Cardiovascular risk factors and ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs, and femoral and abdominal aorta arteries in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"92","author":"Sartorato","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.pharmthera.2011.05.004_bb0570","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000184636","article-title":"Home monitoring of 17 alpha-hydroxyprogesterone levels by filter paper blood spots in patients with 21-hydroxylase deficiency","volume":"44","author":"Shimon","year":"1995","journal-title":"Horm Res"},{"issue":"2","key":"10.1016\/j.pharmthera.2011.05.004_bb0575","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1542\/peds.2006-1612","article-title":"Adrenal insufficiency: still a cause of morbidity and death in childhood","volume":"199","author":"Shulman","year":"2007","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.pharmthera.2011.05.004_bb0580","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0026-0495(97)90186-4","article-title":"Congenital adrenal hyperplasia complicated by central precocious puberty: linear growth during infancy and treatment with gonadotropin-releasing hormone analog","volume":"46","author":"Soliman","year":"1997","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0585","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11154-008-9097-x","article-title":"Nonclassic adrenal hyperplasia","volume":"10","author":"Speiser","year":"2009","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0590","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1056\/NEJMra021561","article-title":"Congenital adrenal hyperplasia","volume":"349","author":"Speiser","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pharmthera.2011.05.004_bb0595","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1172\/JCI115897","article-title":"Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"90","author":"Speiser","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0600","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1210\/jc.2009-2631","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline","volume":"95","author":"Speiser","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0605","series-title":"The Human Gene Mutation Database (HGMD\u00ae): Update","author":"Stenson","year":"2008"},{"issue":"4","key":"10.1016\/j.pharmthera.2011.05.004_bb0610","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0015-0282(03)01006-9","article-title":"Monitoring of menstrual cycles, ovulation, and adrenal suppression by saliva sampling in female patients with 21-hydroxylase deficiency","volume":"80","author":"Stikkelbroeck","year":"2003","journal-title":"Fertil Steril"},{"issue":"4","key":"10.1016\/j.pharmthera.2011.05.004_bb0615","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/01.OGX.0000062966.93819.5B","article-title":"Fertility in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"58","author":"Stikkelbroeck","year":"2003","journal-title":"Obstet Gynecol Surv"},{"issue":"8","key":"10.1016\/j.pharmthera.2011.05.004_bb0620","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1210\/jc.2002-030011","article-title":"Growth inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency: in early infancy and (pre) puberty","volume":"88","author":"Stikkelbroeck","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.pharmthera.2011.05.004_bb0625","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1210\/jc.2002-021681","article-title":"CYP21 gene mutation analysis in 198 patients with 21-hydroxylase deficiency in The Netherlands: six novel mutations and a specific cluster of four mutations","volume":"88","author":"Stikkelbroeck","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmthera.2011.05.004_bb0630","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1515\/JPEM.2004.17.4.645","article-title":"Asymptomatic testicular adrenal rest tumors in adolescent and adult males with congenital adrenal hyperplasia: basal and follow-up investigation after 2.6years","volume":"17","author":"Stikkelbroeck","year":"2004","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0635","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/sj.gt.3301018","article-title":"Restoration of adrenal steroidogenesis by adenovirus-mediated transfer of human cytochrome P450 21-hydroxylase into the adrenal gland of 21-hydroxylase-deficient mice","volume":"6","author":"Tajima","year":"1999","journal-title":"Gene Ther"},{"issue":"3","key":"10.1016\/j.pharmthera.2011.05.004_bb0640","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000295722","article-title":"Ovarian adrenal rest tumor in a congenital adrenal hyperplasia patient with adrenocorticotropin hypersecretion following adrenalectomy","volume":"74","author":"Tiosano","year":"2010","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0645","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/adc.87.2.139","article-title":"Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients","volume":"87","author":"Van der Kamp","year":"2002","journal-title":"Arch Dis Child"},{"issue":"7","key":"10.1016\/j.pharmthera.2011.05.004_bb0650","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1210\/jc.2002-022026","article-title":"The role of bilateral adrenalectomy in the treatment of congenital adrenal hyperplasia","volume":"88","author":"Van Wyk","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmthera.2011.05.004_bb0655","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2265.2009.03636.x","article-title":"A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia","volume":"72","author":"Verma","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"10.1016\/j.pharmthera.2011.05.004_bb0660","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2174\/1389450033490858","article-title":"Melanocortins and their receptors and antagonists","volume":"4","author":"Voisey","year":"2003","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0665","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1210\/jc.2006-1069","article-title":"Altered 24-hour blood pressure profiles in children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"91","author":"V\u00f6lkl","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.pharmthera.2011.05.004_bb0670","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1530\/EJE-08-0770","article-title":"Does an altered leptin axis play a role in obesity among children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency?","volume":"160","author":"V\u00f6lkl","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0675","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/adc.78.6.544","article-title":"Rectal hydrocortisone during stress in patients with adrenal insufficiency","volume":"78","author":"Vroede","year":"1998","journal-title":"Arch Dis Child"},{"issue":"6","key":"10.1016\/j.pharmthera.2011.05.004_bb0680","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/er.21.6.697","article-title":"Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome","volume":"21","author":"Wajchenberg","year":"2000","journal-title":"Endocr Rev"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0685","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1210\/jc.2003-032051","article-title":"Stress dose of hydrocortisone is not beneficial in patients with classic congenital adrenal hyperplasia undergoing short-term, high-intensity exercise","volume":"89","author":"Weise","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.pharmthera.2011.05.004_bb0690","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1210\/jc.2003-030634","article-title":"Patients with classic congenital adrenal hyperplasia have decreased epinephrine reserve and defective glucose elevation in response to high-intensity exercise","volume":"89","author":"Weise","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0700","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1210\/er.21.3.245","article-title":"Congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"21","author":"White","year":"2000","journal-title":"Endocr Rev"},{"issue":"9270","key":"10.1016\/j.pharmthera.2011.05.004_bb0705","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0140-6736(00)04895-9","article-title":"Specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial","volume":"357","author":"Wickman","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0715","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2265.1981.tb02967.x","article-title":"Reversible male infertility due to congenital adrenal hyperplasia","volume":"14","author":"Wischusen","year":"1981","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"10.1016\/j.pharmthera.2011.05.004_bb0720","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1210\/en.2006-0162","article-title":"Differentiation of adult stem cells derived from bone marrow stroma into Leydig or adrenocortical cells","volume":"147","author":"Yazawa","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0725","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/adc.63.6.617","article-title":"17OH-progesterone rhythms in congenital adrenal hyperplasia","volume":"63","author":"Young","year":"1988","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0730","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/adc.63.6.624","article-title":"Androstenedione rhythms in congenital adrenal hyperplasia","volume":"63","author":"Young","year":"1988","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.pharmthera.2011.05.004_bb0735","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000262526","article-title":"Corticotropin-releasing hormone receptor antagonists: an update","volume":"17","author":"Zoumakis","year":"2010","journal-title":"Endocr Dev"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372581100115X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372581100115X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T19:47:23Z","timestamp":1712432843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372581100115X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":143,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S016372581100115X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2011.05.004","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}